Table 2.

Associations between CTC count and baseline characteristics of patients.

Characteristics	n	CTC/7.5 mL		p-Value
		Median	Range
CTC count at baseline	80	6.5	0–1266	-
Docetaxel line				0.3
First-line	53	6	0–891
Second-line	27	9	0–1266
Age (years)				0.13
<Median	40	6	0–567
≥Median	40	7	0–1266
Histology				0.81
Gleason < 8	27	6	0–891
Gleason ≥ 8	53	7	0–1266
M1 at diagnosis				0.27
Yes	45	9	0–1266
No	35	6	0–567
PSA (ng/dL)				0.76
<Median	40	5	0–891
≥Median	40	8.5	0–1266
Metastasis site
Bone	67	7	0–1266	0.35
Lymph node	41	7	0–891	0.4
Visceral	12	10	0–891	0.87
ECOG				0.001
ECOG 0	29	5	0–51
ECOG 1	45	9	0–567
ECOG 2	6	14.5	0–1266
ALP				0.038
Normal	38	5	0–56
Elevated (>ULN)	42	9	2–1266
LDH				0.007
Normal	48	5	0–98
Elevated (>ULN)	32	10	5–1266
Hemoglobin				<0.001
≥10 g/dL	73	6	0–567
<10 g/dL	7	7	0–1266
Albumin				0.07
≥3.5 g/dL	66	6	0–1266
<3.5 g/dL	13	19	6–891

Abbreviations: CTC, circulating tumor cell; PSA, prostate-specific antigen; ECOG, Eastern Cooperative Oncology Group; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; ULN, upper limit of normal; mCRPC, metastatic castration-resistant prostate cancer; ADT, androgen deprivation therapy.